Background: Primary dysmenorrhea is associated with prostaglandin-mediated uterine contractions and menstrual pain. Syzygium cumini leaves contain phenolic compounds and flavonoids with reported biological activities. However, herbal extracts exhibit compositional variability, which may complicate formulation development and reproducibility. Stimuli-responsive polymeric nanogels offer a potential approach to controlling the release of encapsulated phytochemicals. Objective: This study aims to develop, optimize and characterize Syzygium cumini leaf phytochemical-loaded stimuli-responsive polymeric nanogels and investigate their in vitro anti-inflammatory potential relevant to dysmenorrhea. Methods: Authenticated Syzygium cumini leaves will be extracted using a standardized procedure. Phytochemical characterization will include chromatographic fingerprinting and quantification of selected marker compounds. A suitable biocompatible polymer network will be selected according to the intended stimulus. Formulation variables will be optimized using design of experiments. Particle size, polydispersity index, zeta potential, morphology, encapsulation efficiency, loading capacity, stability and marker release under reference and stimulus conditions will be evaluated. Biological studies will compare the loaded formulation with free extract, blank nanogels and appropriate controls. Cell viability and selected inflammatory endpoints, including prostaglandin E2 where justified, will be assessed using validated methods. Expected contribution: The investigation will establish whether the formulation can be prepared reproducibly, demonstrate stimulus-dependent release and provide evidence regarding its comparative biological performance. Conclusion: This study provides an experimental framework for evaluating a responsive herbal nanogel as an early-stage drug-delivery candidate. Actual results must establish its formulation performance and biological value. Clinical effectiveness in dysmenorrhea cannot be inferred without further preclinical and clinical investigation.
Trupti N. Ghorpade*, Prajakta M. Ghuge, Vaishali L. Ghode, Vaishali A. Argade.
Antiretroviral drugs used in HIV treatment often suffer from poor aqueous solubility and low oral bioavailability, resulting in reduced therapeutic effectiveness. Nanosuspension technology has emerged as an effective strategy to improve dissolution rate, absorption and bioavailability of poorly soluble drugs. Nanosuspensions are colloidal dispersions of nanosized drug particles stabilised by surfactants or polymers. Incorporation of nanosuspensions into oral tablet dosage forms combines the benefits of nanotechnology with the convenience and stability of tablets. This review summarises various methods of nanosuspension preparation, formulation approaches, characterisation techniques and evaluation parameters of nanosuspension-based oral tablets containing antiretroviral drugs. The review also highlights recent advancements, advantages, limitations and future perspectives of nanosuspension technology in HIV therapy.
Artificial intelligence (AI) is becoming a crucial part of contemporary healthcare systems, transforming the creation and use of medical technologies in clinical settings. AI has been increasingly incorporated into medical equipment over the past ten years, improving patient monitoring, increasing diagnostic accuracy and providing more individualized treatment alternatives. This thesis examines and interprets the patterns of AI-enabled medical devices that were authorized in the US between 2013 and 2023, paying particular attention to how these devices were distributed throughout different medical specialties. The study groups AI-integrated medical devices into four major categories: Radiology, Cardiovascular, Neurology and Others, using data gathered from the U.S. Food and Drug Administration (FDA). According to the data, radiology has a glaring dominance, which explains the results of the investigation show a clear dominance of the profound integration of AI in medical imaging technologies like MRI, CT and X-ray is demonstrated by radiology, which makes up 77% of all devices. The diagnostic procedures, disease detection rates and data interpretation have all improved thanks to these AI-powered imaging technologies. 10% of all devices are cardiovascular devices, which represent developments in risk assessment, minimally invasive intervention planning and heart health monitoring respectively. With a mere 3% representation, neurology exhibits narrowly focused applications in the development of brain-computer interfaces and the identification of neurological disorders.10% of the information falls under the "Others" group, which includes a broad range of disciplines such clinical chemistry, ophthalmology, gastroenterology-urology and hematology. Despite the very modest level of AI integration in these domains, they nevertheless reflect essential areas for innovation. For example, hematology uses AI to forecast hematopoietic disorders and analyze blood cell morphology. Similarly, advancements in the early detection of vision-related disorders like glaucoma and diabetic retinopathy are being fueled by AI applications in ophthalmology. The number of AI medical devices has been steadily increasing year over year, according to this survey, demonstrating the quick speed of technological development and rising regulatory approval. Because of its data-rich environment and machine learning algorithm compatibility, radiology continues to lead in event submissions and product approvals.